NASDAQ: IMMP
Immutep Ltd Stock Forecast, Predictions & Price Target

Analyst price target for IMMP

Based on 1 analyst offering 12 month price targets for Immutep Ltd

Min Forecast
$7.00+304.62%
Avg Forecast
$7.00+304.62%
Max Forecast
$7.00+304.62%

Should I buy or sell IMMP stock?

Based on 1 analyst offering ratings for Immutep Ltd.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IMMP's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates IMMP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their IMMP stock forecasts and price targets.

IMMP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-11-15

1 of 1

Forecast return on equity

Is IMMP forecast to generate an efficient return?

Company
-348.89%
Industry
146.26%
Market
80.85%
IMMP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMMP forecast to generate an efficient return on assets?

Company
-330.03%
Industry
36.38%
IMMP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMMP earnings per share forecast

What is IMMP's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.30
Avg 2 year Forecast
-$0.30
Avg 3 year Forecast
-$0.40

IMMP revenue forecast

What is IMMP's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$3.8M-44.55%
Avg 2 year Forecast
$2.5M-62.98%
Avg 3 year Forecast
$2.5M-62.98%
IMMP's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IMMP revenue growth forecast

How is IMMP forecast to perform vs Biotechnology companies and vs the US market?

Company
-30.53%
Industry
64.61%
Market
10.18%
IMMP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IMMP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IMMP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMMP$1.73$7.00+304.62%Buy
AVIR$2.95$6.00+103.39%Hold
CMPX$1.84$15.67+751.47%Strong Buy
DSGN$4.39N/AN/A
DBVT$9.08$10.00+10.13%Buy

Immutep Stock Forecast FAQ

Is Immutep Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: IMMP) stock is to Buy IMMP stock.

Out of 1 analyst, 0 (0%) are recommending IMMP as a Strong Buy, 1 (100%) are recommending IMMP as a Buy, 0 (0%) are recommending IMMP as a Hold, 0 (0%) are recommending IMMP as a Sell, and 0 (0%) are recommending IMMP as a Strong Sell.

If you're new to stock investing, here's how to buy Immutep stock.

What is IMMP's earnings growth forecast for 2025-2027?

(NASDAQ: IMMP) Immutep's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.

Immutep's earnings in 2025 is -$27,588,593.On average, 1 Wall Street analyst forecast IMMP's earnings for 2025 to be -$436,676,873, with the lowest IMMP earnings forecast at -$436,676,873, and the highest IMMP earnings forecast at -$436,676,873. On average, 1 Wall Street analyst forecast IMMP's earnings for 2026 to be -$436,676,873, with the lowest IMMP earnings forecast at -$436,676,873, and the highest IMMP earnings forecast at -$436,676,873.

In 2027, IMMP is forecast to generate -$582,235,830 in earnings, with the lowest earnings forecast at -$582,235,830 and the highest earnings forecast at -$582,235,830.

What is IMMP's revenue growth forecast for 2025-2027?

(NASDAQ: IMMP) Immutep's forecast annual revenue growth rate of -30.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.

Immutep's revenue in 2025 is $6,920,900.On average, 1 Wall Street analysts forecast IMMP's revenue for 2025 to be $5,516,684,489, with the lowest IMMP revenue forecast at $5,516,684,489, and the highest IMMP revenue forecast at $5,516,684,489. On average, 1 Wall Street analysts forecast IMMP's revenue for 2026 to be $3,682,641,625, with the lowest IMMP revenue forecast at $3,682,641,625, and the highest IMMP revenue forecast at $3,682,641,625.

In 2027, IMMP is forecast to generate $3,682,641,625 in revenue, with the lowest revenue forecast at $3,682,641,625 and the highest revenue forecast at $3,682,641,625.

What is IMMP's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: IMMP) forecast ROA is -330.03%, which is lower than the forecast US Biotechnology industry average of 36.38%.

What is IMMP's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IMMP price target, the average IMMP price target is $7.00, with the highest IMMP stock price forecast at $7.00 and the lowest IMMP stock price forecast at $7.00.

The Wall Street analyst predicted that Immutep's share price could reach $7.00 by Nov 15, 2025. The average Immutep stock price prediction forecasts a potential upside of 304.62% from the current IMMP share price of $1.73.

What is IMMP's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: IMMP) Immutep's current Earnings Per Share (EPS) is -$0.21. On average, analysts forecast that IMMP's EPS will be -$0.30 for 2025, with the lowest EPS forecast at -$0.30, and the highest EPS forecast at -$0.30. On average, analysts forecast that IMMP's EPS will be -$0.30 for 2026, with the lowest EPS forecast at -$0.30, and the highest EPS forecast at -$0.30. In 2027, IMMP's EPS is forecast to hit -$0.40 (min: -$0.40, max: -$0.40).

What is IMMP's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: IMMP) forecast ROE is -348.89%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.